Journal of Biological Chemistry
Volume 286, Issue 6, 11 February 2011, Pages 4216-4225
Journal home page for Journal of Biological Chemistry

Signal Transduction
Class II Phosphoinositide 3-Kinase Regulates Exocytosis of Insulin Granules in Pancreatic β Cells*

https://doi.org/10.1074/jbc.M110.200295Get rights and content
Under a Creative Commons license
open access

Phosphoinositide 3-kinases (PI3Ks) are critical regulators of pancreatic β cell mass and survival, whereas their involvement in insulin secretion is more controversial. Furthermore, of the different PI3Ks, the class II isoforms were detected in β cells, although their role is still not well understood. Here we show that down-regulation of the class II PI3K isoform PI3K-C2α specifically impairs insulin granule exocytosis in rat insulinoma cells without affecting insulin content, the number of insulin granules at the plasma membrane, or the expression levels of key proteins involved in insulin secretion. Proteolysis of synaptosomal-associated protein of 25 kDa, a process involved in insulin granule exocytosis, is impaired in cells lacking PI3K-C2α. Finally, our data suggest that the mRNA for PI3K-C2α may be down-regulated in islets of Langerhans from type 2 diabetic compared with non-diabetic individuals. Our results reveal a critical role for PI3K-C2α in β cells and suggest that down-regulation of PI3K-C2α may be a feature of type 2 diabetes.

Diabetes
Exocytosis
Insulin Secretion
Phosphatidylinositol 3-Kinase
Signal Transduction

Cited by (0)

*

This work was supported by Barts and The London Charity Grant 430/647, Diabetes Research & Wellness Foundation, and Diabetes UK Grant BDA:09/0003971 (all to T. M.).

The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1–S4.

1

Supported by Barts and The London Charity Grants 430/647 (to T. M.) and RAB/06/PHD/12 (to M. D. T.).

2

Supported by the Pancreatic Cancer Research Fund (to M. F.).

3

Supported by grants from The Wellcome Trust, Medical Research Council, European Union (FP6 “Savebeta”), Juvenile Diabetes Research Foundation, and Diabetes UK.

4

Supported by grants from the European Union (FP6 “EURODIA”).